| アブストラクト | PURPOSE: Routinely collected prescription data provides drug exposure information for pharmacoepidemiology, informing start/stop dates and dosage. Prescribing information includes structured data and unstructured free-text instructions, which can include inherent variability, such as "one to two tablets up to four times a day". Preparing drug exposure data from raw prescriptions to a research ready dataset is rarely fully reported, yet assumptions have considerable implications for pharmacoepidemiology. This may have bigger consequences for "pro re nata" (PRN) drugs. Our aim was, using a worked example of opioids and fracture risk, to examine the impact of incorporating narrative prescribing instructions and subsequent drug preparation assumptions on adverse event rates. METHODS: R-packages for extracting free-text medication prescription instructions in a structured form (doseminer) and an algorithm for transparently processing drug exposure information (drugprepr) were developed. Clinical Practice Research Datalink GOLD was used to define a cohort of adult new opioid users without prior cancer. A retrospective cohort study was performed using data between January 1, 2017 and July 31, 2018. We tested the impact of varying drug preparation assumptions by estimating the risk of opioids on fracture risk using Cox proportional hazards models. RESULTS: During the study window, 60 394 patients were identified with 190 754 opioid prescriptions. Free-text prescribing instruction variability, where there was flexibility in the number of tablets to be administered, was present in 42% prescriptions. Variations in the decisions made during preparing raw data for analysis led to marked differences impacting the event number (n = 303-415) and person years of drug exposure (5619-9832). The distribution of hazard ratios as a function of the decisions ranged from 2.71 (95% CI: 2.31, 3.18) to 3.24 (2.76, 3.82). CONCLUSIONS: Assumptions made during the drug preparation process, especially for those with variability in prescription instructions, can impact results of subsequent risk estimates. The developed R packages can improve transparency related to drug preparation assumptions, in line with best practice advocated by international pharmacoepidemiology guidelines. |
|---|
| ジャーナル名 | Pharmacoepidemiology and drug safety |
|---|
| Pubmed追加日 | 2023/2/1 |
|---|
| 投稿者 | Jani, Meghna; Yimer, Belay Birlie; Selby, David; Lunt, Mark; Nenadic, Goran; Dixon, William G |
|---|
| 組織名 | Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research,;The University of Manchester, Manchester, UK.;NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation;Trust, Manchester Academic Health Science Centre, Manchester, UK.;Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK.;Department of Computer Science, University of Manchester, Manchester, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36718594/ |
|---|
